Spherix Introduces Patient Chart Dynamix™, an Enhanced Independent Pharmaceutical Market Research Chart Audit
26 sept. 2023 14h12 HE
|
Spherix Global Insights
Exton, PA, Sept. 26, 2023 (GLOBE NEWSWIRE) -- Spherix Global Insights, a trusted leader in pharmaceutical market research, is delighted to announce the launch of its latest product, Patient Chart...
Spherix Global Insights Announces New Leadership to Drive Growth and Innovation
21 sept. 2023 16h00 HE
|
Spherix Global Insights
Exton, Pennsylvania, Sept. 21, 2023 (GLOBE NEWSWIRE) -- Spherix Global Insights, a leading provider of market data and insights to the pharmaceutical industry, is thrilled to announce the appointment...
Amgen’s Amjevita Remains the Frontrunner in the US Adalimumab Biosimilars Market, Despite Increased Competition, According to Spherix Global Insights.
14 sept. 2023 11h37 HE
|
Spherix Global Insights
Exton, Pennsylvania, Sept. 14, 2023 (GLOBE NEWSWIRE) -- This summer ushered in the highly anticipated introduction of a multitude of additional adalimumab biosimilars to the dynamic US immunology...
With Little Remaining Unmet Need for Injectable Biologics for the Treatment of Plaque Psoriasis, US Dermatologists Report the Future is Oral, According to Spherix Global Insights
31 août 2023 16h35 HE
|
Spherix Global Insights
Exton, Pennsylvania, Aug. 31, 2023 (GLOBE NEWSWIRE) -- The biologic treatment armamentarium for plaque psoriasis has arguably experienced some of the most successful developments in recent...
Another Medicine to Stop Migraine in its Tracks – Zavzpret™ is Now Available, but Where will Neurologists use it?
17 août 2023 14h57 HE
|
Spherix Global Insights
Exton, Pennsylvania, Aug. 17, 2023 (GLOBE NEWSWIRE) -- In February 2023, Pfizer published their positive Phase 3 clinical trial results for zavegepant (new brand name, Zavzpret™). At the time,...
An Old Dog with a New Trick… Ellodi’s APT-1011 Promises EoE Patients a Convenient and Potent Treatment Alternative
15 août 2023 15h40 HE
|
Spherix Global Insights
Exton, Pennsylvania, Aug. 15, 2023 (GLOBE NEWSWIRE) -- Since launching in May 2022, Sanofi/Regeneron’s Dupixent has been well received by gastroenterologists and allergists as an advancement for...
What’s on Your Must-Read List? If You Work in Pharma, Add Spherix Global Insights’ Generalized Myasthenia Gravis Patient Chart Audit to that List
10 août 2023 15h15 HE
|
Spherix Global Insights
Exton, Pennsylvania, Aug. 10, 2023 (GLOBE NEWSWIRE) -- In one of the largest patient-focused studies ever conducted in gMG, Spherix’s RealWorld Dynamix™: Treatment Patterns in generalized Myasthenia...
How High Is the Bar for Future ALS Treatments? Although Neurologists Express Frustration with Current Treatments, They Are Quick to Adopt Therapies that Promise to Delay ALS Progression
02 août 2023 11h15 HE
|
Spherix Global Insights
Exton, Pennsylvania, Aug. 02, 2023 (GLOBE NEWSWIRE) -- A quiet but significant advance was made during the last year: not one, but two medicines were FDA approved to delay disease progression in the...
Breaking Into a Saturated Relapsing Remitting Multiple Sclerosis Market: Where Should Developers Focus?
01 août 2023 12h02 HE
|
Spherix Global Insights
Exton, Pennsylvania, Aug. 01, 2023 (GLOBE NEWSWIRE) -- Despite outward appearances of being a stagnant market, the relapsing remitting multiple sclerosis (RMS) market continues to offer drug...
First-to-Market Edge for Apellis’s Syfovre in Geographic Atrophy Diminished in the Face of an Unexpected Safety Signal
28 juil. 2023 12h26 HE
|
Spherix Global Insights
Exton, Pennsylvania, July 28, 2023 (GLOBE NEWSWIRE) -- For many who have been following the retina market, the news about the emerging safety signal associated with Apellis’ Syfovre in geographic...